Capsida emerged from stealth mode in May 2021 with $140 million of capital, including $90 million from AbbVie, as part of a multi-year strategic collaboration and option agreement.

In February 2023, Capsida and AbbVie announced an expansion of their strategic collaboration to develop genetic medicines for eye diseases with high unmet need.